Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
New data for heart failure pill could clear the way for use in less severely ill patients.
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
Amarin's huge cardiovascular outcomes study of Vascepa will read out soon, but an emphatic victory looks unlikely.
To topple the king the new crop of diabetes drugs must show clear cardiovascular benefits.
Celegene's fortunes linked to partner Acceleron's success in key late-stage trials.
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.
Strong data in ovarian cancer could determine the opportunity for Parp inhibitor combinations.
Tecentriq narrows gap in first-line lung cancer race with Impower-131 data.